OPT
Opthea
Opthea is a biopharmaceutical company focused on developing innovative biologics-based therapies for treating vision-threatening eye diseases. The company is pioneering the development of sozinibercept, a first-in-class VEGF-C/D 'trap' inhibitor, aimed at improving treatment outcomes for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Shorted
About
website
industry
address
Key Metrics
More Pharmaceuticals, Biotechnology & Life Sciences Stocks
Other shorted stocks in this sector
Short Position Trends
Track bearish sentiment and short interest over time
Historical Price Data
View stock price movements, volume, and trading patterns
Industry & Focus
Company Overview
AI-generated company summary
Opthea is a biopharmaceutical company focused on developing innovative biologics-based therapies for treating vision-threatening eye diseases. The company is pioneering the development of sozinibercept, a first-in-class VEGF-C/D 'trap' inhibitor, aimed at improving treatment outcomes for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).
Company History
Opthea was founded with the mission to improve the lives of individuals affected by blinding eye diseases. Over the years, the company has focused on developing novel therapies, with its lead product candidate, sozinibercept, currently in Phase 3 development. Opthea aims to be the first in 20 years to introduce a new therapy that significantly enhances the quality of life for patients with wet AMD.
Competitive Advantages
Opthea's competitive advantages include its focus on biologics-based therapies, its pioneering approach with sozinibercept as a VEGF-C/D 'trap' inhibitor, and its commitment to addressing unmet needs in the treatment of wet AMD and DME.
Risk Factors
- •Regulatory approval challenges
- •Clinical trial risks
- •Market competition
Recent Developments
Last 6 months
Opthea has been advancing its lead product candidate, sozinibercept, through Phase 3 clinical trials, aiming to establish it as a new standard in the treatment of wet AMD.
Key People
Leadership team at Opthea
Jeremy M. Levin
Chair
Jeremy M. Levin serves as the Chairman of the Board at Opthea, bringing extensive experience in the pharmaceutical industry.
Kathy Connell, GAICD
Non-Executive Director
Kathy Connell is a Non-Executive Director and Chair of the Remuneration Committee, contributing her expertise in governance and strategic oversight.